Asian Pac J Cancer Prev, 18 (11), 3031-3039

Introduction

Myeloid malignancies are described as a clonal disorder occurring in hematopoietic stem cells (HSCs) and myeloid progenitor cells. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are also included in the group of myeloid malignancies (Murati et al., 2012). The disorder in proliferation and differentiation of hematopoiesis leads to the accumulation of blast cells in bone marrow (BM) and peripheral blood (PB). Approximately 31% of MDS patients eventually developed an AML (Bains et al., 2011). In AML and MDS patients, 40-45% have CN-AML and CN-MDS (Gregory et al., 2009; Grossmann et al., 2012). These patients are classified as intermediate risk AML by the Medical Research Council (MRC) and Southwest Oncology Group (SWOG) (Grimwade et al., 1998; Slovak et al., 2000). Nowadays, cytogenetic results are important data for treatment. However, the heterogeneity among the intermediate risk CN-AML patients has a range of five years for an overall survival rate between 24-42% (Gregory et al., 2009). In addition the treatment plan remains controversial. Many molecular markers in CN-AML have been identified in various research studies and can be used to make an accurate prognosis. These markers may be employed to decide treatment and identify novel target therapies for normal karyotype patients in the future (Gregory et al., 2009). Previous studies have reported that various gene mutations play a role in leukemogenesis and the prognostic factors in CN-AML and CN-MDS patients. Fms-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD), Nucleophosmin (NPM1),
and DNA methyltransferase 3A (DNMT3A) mutations were frequently found in CN-AML cases (Lin et al., 2011). FLT3-ITD mutation (FLT3-ITDmut) was frequently found in exon 14-15 in 22.4-38.0% of the CN-AML patients (Kim et al., 2010; Park et al., 2012), whereas CN-MDS patients revealed the occurrence of FLT3-ITD mutations at only 2.2% (Bains et al., 2011). NPM1 mutation (NPM1mut) primarily presented in exon 12 in 38.3-53.1% of CN-AML and 10.8% of CN-MDS (Schlenk et al., 2008; Bains et al., 2011; Park et al., 2012). DNMT3A mutation (DNMT3Amut) was frequently detected in exon 23 in 13.3-34.2% of CN-AML (Marcucci et al., 2012; Ahmad et al., 2014) and 6.3% of CN-MDS patients (El Ghannam et al., 2014). These gene mutations were associated with demographic and clinical parameters, for example gender, white blood cell (WBC) count, platelet count, and BM blast cells in the patients (Dohner et al., 2005; Marcucci et al., 2012). The frequency and type of gene mutations were different among various populations. Many risk factors for AML and MDS have been identified (Nisse et al., 2001; Ma et al., 2010). However, an association of risk factors with gene mutations is not yet well established, particularly in CN-AML and CN-MDS of Thai population. From the cancer registry of Thailand in the period of 2010-2012, leukemia was ranked as the tenth leading form of cancer among both male and female patients (Imsanarn et al., 2015). The provinces in upper Northern Thailand are situated in valleys that are surrounded by high mountains. People in upper Northern Thailand are exposed to smoke haze caused by forest fires or burning of agricultural fields. Moreover, the people in Northern Thailand have a different genetic backgrounds from the other parts of Thailand (Wangkumhang et al., 2013). Therefore, this study aimed to investigate the frequency and type of FLT3-ITD, NPM1, and DNMT3A mutations that are present in this region, and to evaluate the risk factors that influence the mutations of these three genes for a useful and better understanding of the molecular leukemogenetic steps and with a hope in the prevention of carcinogenesis in upper Northern Thailand.

Materials and Methods

Patients and Samples

Bone marrow specimens of adult newly diagnosed AML and MDS patients were obtained from the Division of Hematology, Department of Internal Medicine, Maharaj Nakorn Chiang Mai Hospital, Thailand. The specimens were cultured for karyotyping. The 100 BM specimens of AML (n = 40) and MDS (n = 60) patients who had normal karyotype were examined to identify gene mutations. The informed consents forms were signed by all patients who participated in this study according to the protocols of the Ethics and Research Committee of the Faculty of Medicine, Chiang Mai University.

Cytogenetics

Karyotyping was conducted by following the modifying method (Sun NC, 1974). BM specimens were cultured in RPMI 1640 medium containing fetal bovine serum, antibiotics, and colchicine at 37 °C overnight. After being treated with colcemid at 37 °C for 30 minutes, metaphase chromosomes were harvested by being washed with phosphate buffer saline (PBS), treating them with 0.075 M KCl, fixing cell membranes with methanol: acetic acid (3:1), and then spreading the cells on slides and staining them with the G- or Q-banding methods. Metaphase chromosomes were analyzed under a light or fluorescence microscope and chromosomes were karyotyped according to the International System for Human Cytogenetic Nomenclature (2016).

Identification of Gene Mutations

DNA was extracted from BM specimens by modifying a standard inorganic salting out protocol (Seielstad et al., 1999). Briefly, specimens were treated three times with red cell lysis buffer, and lysed white cell pellets with white cell lysis buffer. After that, lysisate was treated with proteinase K solution (20 mg/ml) at 56°C. Protein was then precipitated using 6M NaCl. The supernatant was collected and DNA was precipitated using cold isopropanol. The DNA pellets were washed twice with a solution of 70% cold ethanol. Then, 50-100 µl of Tris EDTA (TE) buffer was resuspended into DNA pellets. Polymerase chain reaction (PCR) was performed on exon 14-15 for FLT3-ITD, exon 12 for NPM1, and exon 23 for DNMT3A (currently, those were exon 14-15, exon 11, and exon 26, respectively in NCBI). The sequence of primers included forward-5'-CTCAGAAGCTCTATTCCTCTAC-3', reverse-5'-AGAAGGCGATGGGTTGGAAAC-3' for FLT3-ITD; forward-5'-TTAATCTCTGTTGTTAGATGAA-3', reverse-5'-CAAGACTATTTGCACTCATTCAAC-3' for NPM1 (Dohner et al., 2005); and forward-5'-TCCGTGTGTGTTAGACG-3', reverse-5'-ATGATGTCACCCCCTTTGCGA-3' for DNMT3A (Thol et al., 2011). PCR cycle was run according to MyTaq HS polymerase condition (Bioline, London, UK), with an initial denaturation step at 95°C for one minute, followed by 35 cycles at 95°C for 15 seconds, 58°C for 15 seconds, 72°C for one minute on a thermal cycler (Eppendorf Mastercycler, USA). The PCR products were purified using GeneJET PCR Purification Kits (Thermo scientific, USA) and were labeled with 0.5 µl of BigDye Terminator V3.1 (Applied Biosystems, Foster City, California, USA). For all mutations, PCR and sequencing were performed again for confirmation. Sequencing was conducted in both directions, while only reverse sequence was performed for NPM1 by using the primers as PCR. Sequencing reactions were purified using the ethanol/EDTA/Sodium acetate precipitation method and capillary electrophoresis was run on an ABI Prism® 3130 DNA Analyzer (Applied Biosystems, Foster City, California, USA) or Applied Biosystems 3730xl DNA Analyzer (Applied Biosystems, Foster City, California, USA), and the electropherograms were analyzed for gene mutations by comparing with the reference DNA sequence using the Seqscape program V2.5 (Applied Biosystems, Foster City, California, USA). For all mutations, PCR and sequencing were performed again for confirmation. The reported mutation sequences were based on coding DNA reference sequences of FLT3 (NM_004119.2), NPM1 (NM_002520.6), and DNMT3A (NM_022552.4) from GenBank.
Risk Factors

The risk factors were studied by interviewing the patients or their relatives using questionnaires at a follow-up appointment. The clinical characteristics of the patients were collected from the electronic medical records of Maharaj Nakorn Chiang Mai Hospital.

Statistical Analysis

For all patients, characteristics and clinical data were presented as medians and interquartile ranges (IQRs) for continuous variables and as counts and percentages for categorical variables. For continuous variables were used and dichotomized as follows: age ≤ 60 years and BMI < 25 kg/m². Fisher’s exact test and Wilcoxon-Mann-Whitney tests were performed to compare characteristics between groups. The association between gene mutation and risk factors were analyzed by logistic regression test. Factors associated with a P-value of lower than 0.10 through the univariate analysis were included in the multivariate analysis. All reported P-values were 2-sided and P-values < 0.05 were considered statistically significant. Statistical analysis was performed using SPSS Version 17.0.

Results

Characteristics and Clinical Data of CN-AML and CN-MDS Patients

There were 40 (40.0%) CN-AML and 60 (60.0%) CN-MDS of a total of 100 newly diagnosed AML and MDS patients. The general characteristics of the patients are presented in Table 1.

Frequency and Type of Gene Mutations

The most frequently mutated genes were FLT3-ITD (10.0%), followed by NPM1 (7.0%), and DNMT3A (4.0%) of all 100 patients. Since these gene mutations were not found in CN-MDS, the frequency of the mutations in CN-AML patients were 25.0%, 17.5%, and 10.0% for FLT3-ITD, NPM1, and DNMT3A, respectively.

FLT3-ITD Mutation

FLT3-ITD\textsuperscript{mut} was found in 10 out of 40 of the CN-AML cases (25.0%). The patterns of FLT3-ITD\textsuperscript{mut} were shown in three patterns (Figure 1). The pure single duplicated ITD pattern was presented in five cases (case 3, 5, 8, 9, and 10) with the duplicated sequence in 60, 90, 36, 69, and 72 nucleotides, respectively. The insertion before duplicated ITD pattern was found in four cases (case 1, case 4, case 6, and case 7) that showed an insertion of nucleotides with a length of 3, 9, 2, and 2 nucleotides before the duplicated sequence in 21, 150, 106, and 34 nucleotides, respectively. The double duplicated ITD pattern was presented in one case (case 2) with the duplicated sequence in 18 and 78 nucleotides. Therefore, these three patterns were illustrated for 11 types of FLT3-ITD\textsuperscript{mut} with the sizes of mutant ITD sequence varying from 18 to 159 nucleotides.

NPM1 Mutation

NPM1\textsuperscript{mut} was found in seven cases (17.5%) of CN-AML, of which, there were three types of NPM1\textsuperscript{mut} (Figure 2).

Table 1. Characteristics and Clinical Data of CN-AML and CN-MDS Patients (N = 100)

| Characteristics | Total | CN-AML | CN-MDS |
|-----------------|-------|--------|--------|
| N, number of patients | 100 (%) | 40 (%) | 60 (%) |
| 1. Gender | | | |
| Male | 35 (35.0%) | 12 (30.0%) | 23 (38.3%) |
| Female | 65 (65.0%) | 28 (70.0%) | 37 (61.7%) |
| 2. Age (years), Median (IQR) | 55.1 (20.0) | 48.5 (21.0) | 61.5 (20.0) |
| 3. Occupation | | | |
| Armed Forces | 2 (2.0%) | 1 (2.5%) | 1 (1.7%) |
| Professional | 6 (6.0%) | 1 (2.5%) | 5 (8.3%) |
| Technician | 7 (7.0%) | 5 (12.5%) | 2 (3.3%) |
| Clerk | 3 (3.0%) | 3 (7.5%) | 0 (0%) |
| Service Worker | 1 (1.0%) | 1 (2.5%) | 0 (0%) |
| Agriculture | 22 (22.0%) | 7 (17.5%) | 15 (25.0%) |
| Trade Worker | 18 (18.0%) | 7 (17.5%) | 11 (18.3%) |
| Elementary | 29 (29.0%) | 12 (30.0%) | 17 (28.3%) |
| Student | 3 (3.0%) | 3 (7.5%) | 0 (0%) |
| Housewife | 6 (6.0%) | 0 (0%) | 6 (10.0%) |
| Retired Worker | 3 (3.0%) | 0 (0%) | 3 (5.0%) |
| 4. BMI (kg/m²) | | | |
| <25 | 75 (81.5%) | 29 (82.9%) | 46 (80.7%) |
| ≥25 | 17 (18.5%) | 6 (17.1%) | 11 (19.3%) |
| 5. Hemoglobin; (g/dl); Median (IQR) | 8.4 (2.6) | 7.6 (2.0) | 8.8 (3.1) |
| 6. WBC; (x10⁹/L); Median (IQR) | 4.9 (5.7) | 12.7 (35.6) | 4.3 (3.3) |
| 7. Platelet; (x10⁹/L); Median (IQR) | 60.0 (136.8) | 46.0 (70.0) | 91.0 (174.1) |
| 8. % blast in bone marrow; Median (IQR) | 3.0 (59.0) | 70.0 (43.0) | 1.0 (2.0) |

Figure 1. (A) Nucleotide Positions of Duplicated Sequence and Patterns of Mutations of FLT3-ITD, (B) Example of Pattern of Duplicated Sequences of Case 8
The most frequent mutation was c.863_864insTCTG (Type A), which was identified in 12.5% of CN-AML patients or in 50.0% of the patients with the NPM1 mutation. The remaining two types included the insertion of four base pairs of CTGC insertions between positions 860 and 861 in one case (2.5% of CN-AML), already reported in the catalogue of somatic mutations in cancer (COSMIC) database. The insertion of four base pairs of CTCT insertions between positions 863 and 864 was also shown in one case (2.5% of CN-AML), and this type has not been reported previously in the COSMIC database.

**DNMT3A Mutation**

DNMT3Amut was detected in only four out of 40 CN-AML cases (10.0%). There were three types of missense mutations, which involved protein changes including R882P (2.5%), R882C (5.0%), and R882H (2.5%) among CN-AML patients (Figure 3).

---

Table 2. Demographic and Clinical Data of 40 CN-AML Patients with Wild Type and Mutation of FLT3-ITD, NPM1, DNMT3A

| Characteristic | Wild type | Mutant | P-value | Wild type | Mutant | P-value | Wild type | Mutant | P-value |
|---------------|-----------|--------|---------|-----------|--------|---------|-----------|--------|---------|
| Gender *      | 0.231     | 0.652  | 1       |           |        |         |           |        |         |
| Male; N (%)   | 11 (36.7) | 1 (0.0) | 1       | 11 (33.3) | 1 (14.3) | 1 (25.0) | 11 (30.6) | 1 (25.0) |         |
| Female; N (%) | 19 (63.3) | 9 (90.0) |         | 22 (66.7) | 6 (85.7) |         | 25 (69.4) | 3 (75.0) |         |
| Age †         | 48.5      | 48     | 0.463   | 47        | 58     | 0.024*  | 47.5      | 51.5    | 0.787   |
| Hb †          | 7.5       | 7.6    | 0.595   | 7.6       | 6.9    | 0.094   | 7.6       | 7.7     | 0.821   |
| WBC †         | 7.7       | 28.3   | 0.303   | 16.6      | 6.4    | 0.817   | 6.6       | 103     | 0.005*  |
| Platelet †    | 50.4      | 30.5   | 0.235   | 49.7      | 27.8   | 0.455   | 39.4      | 52.7    | 0.857   |
| BM Blast †    | 70        | 84.5   | 0.134   | 74        | 70     | 0.773   | 72        | 75      | 0.75    |
| FLT3-ITD ‡    | 1         |        |         |           |        |         |           |        |         |
| Wild Type; N (%) | -         | -      |         | 25 (75.8) | 5 (71.4) |         | 28 (77.8) | 2 (50.0) |         |
| Mutant; N (%)  | -         | -      |         | 8 (24.2)  | 2 (28.6) |         | 8 (22.2)  | 2 (50.0) |         |
| NPM1 ‡        | 1         |        |         |           |        |         |           |        |         |
| Wild Type; N (%) | 25 (83.3) | 8 (80.0) |         | 30 (83.3) | 3 (75.0) |         |           |        |         |
| Mutant; N (%)  | 5 (16.7)  | 2 (20.0) |         | 6 (16.7)  | 1 (25.0) |         |           |        |         |
| DNMT3A ‡      | 0.256     | 0.552  |         |           |        |         |           |        |         |
| Wild Type; N (%) | 28 (93.3) | 8 (80.0) |         | 30 (90.9) | 6 (85.7) |         |           |        |         |
| Mutant; N (%)  | 2 (6.7)   | 2 (20.0) |         | 3 (9.1)   | 1 (14.3) |         |           |        |         |

* P-value <0.05 was considered statistically significant; † Gender and correlation between genes were analyzed by Fisher’s exact test; ‡ Age, hemoglobin, white blood cell count, platelet count, and % of bone marrow blast, were analyzed by Wilcoxon-Mann-Whitney tests.
### Table 3. Univariate and Multivariate Analyses of Risk Factors and 3 Genes Mutations in 100 Patients

| Variable                        | n/N          | OR (95% CI)        | P-value |
|--------------------------------|--------------|--------------------|---------|
| **Univariate Analysis**        |              |                    |         |
| Sex                            |              |                    |         |
| Male                           | 3/35 (8.6%)  | 1                  | 0.148   |
| Female                         | 13/65 (20.0%)| 2.67 (0.71, 10.09) |         |
| Age                            |              |                    |         |
| ≤60 Years                      | 14/63 (22.2%)| 5.00 (1.07, 23.41) | 0.041*  |
| >60 Years                      | 2/37 (5.4%)  | 1                  |         |
| Occupation                      |              |                    |         |
| Student/Retired                | 1/13 (7.7%)  | 1                  |         |
| Worker/Housewife               | 13/65 (20.0%)| 3.00 (0.36, 25.21) | 0.337   |
| Agriculture                    | 2/22 (9.1%)  | 1.20 (0.10, 14.70) | 0.887   |
| Residing in Upper Northern Thailand |  |                |         |
| 1-20 Years                     | 2/13 (15.4%) | 1                  |         |
| 21-40 Years                    | 5/19 (26.3%) | 1.96 (0.32, 12.12) | 0.467   |
| 41-60 Years                    | 7/40 (17.5%) | 1.17 (0.21, 6.47)  | 0.86    |
| > 60 Years                     | 2/28 (7.1%)  | 0.42 (0.05, 3.40)  | 0.418   |
| BMI, (Kg/M²)                   |              |                    |         |
| < 25                            | 12/75 (16.0%)| 1                  |         |
| ≥ 25                            | 2/17 (11.8%) | 0.70 (0.14, 3.47)  | 0.662   |
| (Missing 8)                    |              |                    |         |
| History of Hypertension        |              |                    |         |
| No                             | 9/77 (11.7%) | 1                  |         |
| Yes                            | 7/23 (30.4%) | 3.31 (1.07, 10.21) | 0.038*  |
| History of Diabetes            |              |                    |         |
| No                             | 14/90 (15.6%)| 1                  |         |
| Yes                            | 2/10 (20.0%) | 1.36 (0.26, 7.07)  | 0.717   |
| Family History of Cancer       |              |                    |         |
| No                             | 8/74 (10.8%) | 1                  |         |
| Yes                            | 8/26 (30.8%) | 3.67 (1.21, 11.13) | 0.022*  |
| Smoking                        |              |                    |         |
| Nonsmoker/Passive Smoker       | 14/68 (20.6%)| 1                  |         |
| Smoker                         | 2/32 (6.2%)  | 0.26 (0.06, 1.21)  | 0.085   |
| Alcohol Consumption            |              |                    |         |
| Nondrinker                     | 11/52 (21.2%)| 1                  |         |
| Drinker                        | 5/48 (10.4%) | 0.43 (0.14, 1.36)  | 0.151   |
| Vegetable Consumption          |              |                    |         |
| No                             | 6/46 (13.0%) | 1                  |         |
| Yes                            | 10/54 (18.5%)| 1.52 (0.51, 4.55)  | 0.459   |
| Fruit Consumption              |              |                    |         |
| No                             | 5/36 (13.9%) | 1                  |         |
| Yes                            | 11/64 (17.2%)| 1.29 (0.41, 4.05)  | 0.666   |
| Coffee Consumption             |              |                    |         |
| No                             | 8/66 (12.1%) | 1                  |         |
| Yes                            | 8/34 (23.5%) | 2.23 (0.76, 6.60)  | 0.147   |
| Exercise                       |              |                    |         |
| No                             | 12/63 (19.0%)| 1                  |         |
| Yes                            | 4/37 (10.8%) | 0.52 (0.15, 1.73)  | 0.284   |
| Good Sleep                     |              |                    |         |
| No                             | 2/19 (10.5%) | 1                  |         |
| Yes                            | 14/81 (17.3%)| 1.78 (0.37, 8.57)  | 0.475   |
| Benzene Exposure               |              |                    |         |
| No                             | 13/68 (19.1%)| 1                  |         |
| Yes                            | 3/32 (9.4%)  | 0.44 (0.12, 1.66)  | 0.225   |
| Insecticide Exposure           |              |                    |         |
| No                             | 14/68 (20.6%)| 1                  |         |
| Yes                            | 2/32 (6.2%)  | 0.26 (0.06, 1.21)  | 0.085   |
| Thinner Exposure               |              |                    |         |
| No                             | 13/79 (16.5%)| 1                  |         |
| Yes                            | 3/21 (14.3%) | 0.85 (0.22, 3.29)  | 0.81    |
| Microwave User                 |              |                    |         |
| No                             | 13/73 (17.8%)| 1                  |         |
| Yes                            | 3/27 (11.1%) | 0.58 (0.15, 2.21)  | 0.422   |
| X-Ray Exposure                 |              |                    |         |
| No                             | 6/31 (19.4%) | 1                  |         |
| Yes                            | 10/69 (14.5%)| 0.71 (0.23, 2.15)  | 0.541   |
| Exhaust Gases Exposure         |              |                    |         |
| No                             | 9/51 (17.6%) | 1                  |         |
| Yes                            | 7/49 (14.3%) | 0.78 (0.27, 2.82)  | 0.647   |
| Hair Dye Exposure              |              |                    |         |
| No                             | 12/59 (20.3%)| 1                  |         |
| Yes                            | 4/41 (9.8%)  | 0.42 (0.13, 1.42)  | 0.164   |
| House Near Road                |              |                    |         |
| No                             | 10/51 (19.6%)| 1                  |         |
| Yes                            | 6/49 (12.2%) | 0.57 (0.19, 1.72)  | 0.319   |
| House Near Garden or Farm      |              |                    |         |
| No                             | 9/55 (16.4%) | 1                  |         |
| Yes                            | 7/45 (15.6%) | 0.94 (0.32, 2.77)  | 0.913   |
| Residing in Smoke Haze of Burning Area |  |     |         |
| No                             | 2/9 (22.2%)  | 1                  |         |
| Yes                            | 14/91 (15.4%)| 0.64 (0.12, 3.39)  | 0.596   |
| **Multivariate Analysis**      |              |                    |         |
| Variable                       | n/N          | Adjusted OR (95% CI) | P-value |
| Age                            |              |                    |         |
| ≤60 Years                      | 14/63 (22.2%)| 7.85 (1.49, 41.28) | 0.015*  |
| >60 Years                      | 2/37 (5.4%)  | 1                  |         |
| History of Hypertension        |              |                    |         |
| No                             | 9/77 (11.7%) | 1                  |         |
| Yes                            | 7/23 (30.4%) | 5.38 (1.51, 19.20) | 0.010*  |
| Family History of Cancer       |              |                    |         |
| No                             | 8/74 (10.8%) | 1                  |         |
| Yes                            | 8/26 (10.8%) | 2.71 (0.79, 9.39)  | 0.115   |
| Smoking                        |              |                    |         |
| Nonsmoker/Passive Smoker       | 14/68 (20.6%)| 1                  |         |
| Smoker                         | 2/32 (6.2%)  | 0.55 (0.09, 3.27)  | 0.508   |
| Insecticide Exposure           |              |                    |         |
| No                             | 14/68 (20.6%)| 1                  |         |
| Yes                            | 2/32 (6.2%)  | 0.29 (0.06, 1.50)  | 0.139   |

*P-value < 0.05 was considered statistically significant; n/N, number of patient with mutations/number of patients

**Asian Pacific Journal of Cancer Prevention, Vol 18** 3035
FLT3-ITD, NPM1, DNMT3A Mutations with Demographic, Clinical Data and Gene Mutations

Sixteen of 40 CN-AML patients revealed the presence of gene mutations. They included two cases with mutations of both FLT3-ITD and NPM1 (AML \((\text{FLT3-ITD}/\text{NPM1})\)); two cases with FLT3-ITD and DNMT3A (AML \((\text{FLT3-ITD}/\text{DNMT3A})\)); one case with NPM1 and DNMT3A (AML \((\text{NPM1}/\text{DNMT3A})\)); six cases with FLT3-ITD only (AML \((\text{FLT3-ITD})\)); four cases with NPM1 only (AML \((\text{NPM1})\)); and one case with DNMT3A only (AML \((\text{DNMT3A})\)). No patients revealed having all three gene mutations (AML \((\text{FLT3-ITD}/\text{NPM1}/\text{DNMT3A})\)).

A comparison of demographic clinical data and these gene mutations was analyzed in only CN-AML cases (Table 2). \(\text{NPM1}^{\text{mut}}\) was associated with older age compared to wild type (58 vs 47 years). In addition, \(\text{DNMT3A}^{\text{mut}}\) patients had higher WBC count than those with wild type.

The Risk Factors and All Mutation of FLT3-ITD, NPM1, DNMT3A Genes in CN-AML and CN-MDS Patients (\(N = 100\))

The variables of risk factors including demographic data, health information, the risk of smoking, alcohol consumption, lifestyle, occupational exposure, and environmental exposure were determined for their associations with mutant and wild type cases by univariate logistic regression (Table 3). Three factors correlated to three genes mutations with significant differences. The patients with the age \(\leq\) 60 years had a five-fold risk of mutation (OR = 5.00, 95% CI = 1.07-23.41) compared to patients > 60 years. Patients with history of hypertension had a three-fold (OR = 3.31, 95% CI = 1.07-10.21) higher significant risk of mutation compared to non-history of hypertensive patients. Patients with a family history of cancer showed nearly a four-fold degree of significant risk (OR = 3.67, 95% CI = 1.21-11.13) compared to groups that did not have cancer in family.

The multivariate analysis was adjusted for age, history of hypertension, family history of cancer, smoking, and insecticide exposure (Table 3). After adjustment, the risk of three genes mutations increased significantly in patients who had an age of less than or equal to 60 years (OR = 7.85, 95% CI = 1.49-41.28), and patients with a history of hypertension (OR = 5.38, 95% CI = 1.51-19.20).

Discussion

Gene mutations were studied among many populations of AML but have been less reported among MDS, especially in the normal karyotype. The frequency of gene mutations was different among each population (Fernandez-Mercado et al., 2012; Park et al., 2012; Ahmad et al., 2014). In this study, the hotspot mutation exons of FLT3, NPM1, and DNMT3A genes sequencing were performed among all CN-AML and CN-MDS patients. This study showed these gene mutations were detected only in the CN-AML patients.

\(\text{FLT3-ITD}^{\text{mut}}\) was found in 25.0% of CN-AML. When comparing the frequency of mutations in only normal karyotype of AML patient from previous reports, the frequency of mutations in this study was lower than in Western countries (47.9% in UK (Fernandez-Mercado et al., 2012); 31.0% in Germany (Schlenk et al., 2008)). However, in Asian population, the frequency of mutations in CN-AML were 19.7% in China (Wang et al., 2010), 22.4% in Korea (Park et al., 2012), and 34.6% in Egypt (Shamaa et al., 2014). In Thailand, \(\text{FLT3-ITD}\) mutations were found in 24.6% and 19.2% from the studies in Central and Northeast Thailand, respectively (Auewarakul et al., 2005; Kumsaen et al., 2016). However, frequency of these mutations could not be compared with in this research because the previous papers did not clearly show the number of normal karyotype patients. \(\text{FLT3-ITD}^{\text{mut}}\) was not detected in CN-MDS patients in this study, similar to studies of Rocquain (2010) that did not find \(\text{FLT3-ITD}^{\text{mut}}\) in CN-MDS (Rocquain et al., 2010). Previous investigations also detected its presence in a low frequency (2.2%) in CN-MDS (Bains et al., 2011). Although MDS patients displayed a low frequency of these gene mutations, they are important in predicting AML progression (Bains et al., 2011). The sizes of the mutant ITD fragments varied from 18-159 bp in this study. The lengths of mutant fragments were found to be different in many reports and varied from 3 to 165 bp in India (Ahmad et al., 2010), 21 to 201 bp in Central Thailand (Auewarakul et al., 2005), 27 to 171 bp in Northeast Thailand (Kumsaen et al., 2016), and 26 to 57 bp in China (Zhong et al., 2012). Increasing ITD size leads to a decrease in the overall survival (OS) and relapse free survival (RFS) of patients (Stirewalt et al., 2006). Zhong et al., (2012) classified \(\text{FLT3-ITD}^{\text{mut}}\) into two types and identified them as Type I and Type II. Type I ITD had duplicated sequences without insertion nucleotides, but Type II ITD had an insertion before the duplicated sequences. Consequently, there were seven Type I (6 cases) and four Type II (4 cases) in this study and these results corresponded with the findings of previous studies that Type I was more prevalent than Type II (Auewarakul et al., 2005; Ahmad et al., 2010). AML patients who had \(\text{FLT3-ITD}^{\text{mut}}\) with Type I tended to have significantly worse OS than Type II or the wild type (Zhong et al., 2012). The single ITDs were found more than double ITDs in this study which was in accordance with previous studies, while some studies showed triple ITDs (Ahmad et al., 2010). \(\text{FLT3}\) gene is expressed in the normal hematopoietic stem cell/progenitor cells and important for lymphohematopoietic stem cell function. \(\text{FLT3-ITD}\) mutation activates signaling via RAS-MAP/akt kinase and the STAT5 pathway. This mutation may increase reactive oxygen species (ROS) production, DNA damage and misrepair, leukemic transformation, and chemotherapy resistance (Salimyr et al., 2008).

\(\text{NPM1}^{\text{mut}}\) was observed in 17.5% of CN-AML patients in the current study, a lower frequency than those of many previous studies from Western and Asia (Schlenk et al., 2008; Park et al., 2012). Moreover, frequency of \(\text{NPM1}^{\text{mut}}\) in this study also lower than those of CN-AML in a study of Central Thailand where the frequency was 38.1% (Boonthimat et al., 2008). The differences in these mutation frequencies may be due to many different factors including the genetic backgrounds of each population (Wangkumhang et al., 2013), geographic region and environmental factors. \(\text{NPM1}^{\text{mut}}\) are rare in MDS patients.
(Rocquain et al., 2010; Bains et al., 2011) and this gene mutation in MDS patients was not found in this study, similar to a previous study (Rocquain et al., 2010). A previous study reported that approximately 80% of mutant NPM1 were Type A mutation (Park et al., 2012), and we found that Type A NPM1mut was detected more than Non-Type A. The frequency of Type A NPM1mut in this study was 50.0% among NPM1 mutant patients, while the mutation was 79.2% among the Korean population (Park et al., 2012). Several studies supported our data that NPM1mut was significantly associated with older age than those in wild type, but the mean or median age in the two age groups was ≤ 60 years (Boonthimat et al., 2008; Jeon et al., 2013). Moreover, NPM1mut was reported to be more common in older age than in younger age patients (Boonthimat et al., 2008). NPM1 gene regulates the translocation of nucleophosmin (NPM) protein between the nucleus and cytoplasm (Borer et al., 1989). It plays an important role in the alternate-reading-frame protein (ARF)-p53 tumor-suppressor pathway and NPMmut causes accumulation of NPM in the cytoplasm, which is a critical step in malignant transformation (Falini et al., 2005; Colombo et al., 2006).

DNMT3Amut was found in 10.0% of CN-AML but other studies reported the incidence range of 13.3%-34.2% in CN-AML (Marcucci et al., 2012; Ahmad et al., 2014). In addition, the frequency of DNMT3Amut in CN-AML from Central Thailand were four in 46 patients (8.7%) (Sirirat et al., 2017). No CN-MDS patients had DNMT3Amut in this study, whereas previous studies had 6.3% of the cases (El Ghannam et al., 2014). CN-AML patients in this study showed R882C in two cases, while R882P and R882H were each in one single case. However, R882H, R882C, R882S and R882P were also reported, and R882H was the most frequent pattern (Marcucci et al., 2012). Similar to previous studies Hou et al., (2012) and Marcucci et al., (2012), our patients carrying DNMT3Amut had a significantly higher WBC than the wild type patients. DNMT3Amut was associated with higher WBC and poor prognosis in de novo AML (Hou et al., 2012). WBC counts in DNMT3Amut were higher than those in wild type cases (Markova et al., 2012). The reason is that the proportion of co-mutation AMLFLT3-ITDNMT3A is higher than those among the AMLDNMT3A patients. When lacking co-mutation with FLT3-ITD, WBC counts had no differences between DNMT3Amut and wild type patients (Markova et al., 2012). In this study, the incidence of AMLFLT3/DNMT3A mutations was also higher than AMLDNMT3A only. DNMT3A gene encodes the DNA methyltransferase (DNMT) 3A enzyme, which catalyzes the addition of the methyl group to the fifth position of the cytosine residue of the CpG dinucleotide of DNA to generate 5-methylcytosine (Brenner and Fuks, 2006). The down regulation of the target gene was mediated via the methylation of upstream CpG islands. Therefore, DNMT3Amut leads to an alteration of enzyme function and disrupts the tetramerization activity of DNMT3A, which may have contributed to initiate the oncogenesis (Holz-Schietinger et al., 2012).

The incidence of FLT3-ITD, NPM1, and DNMT3A mutations in CN-MDS was fewer than in CN-AML patients (Bains et al., 2011; Swelam et al., 2011; El Ghannam et al., 2014). No mutation of these genes was observed in the current study, which corresponded with the report of an absence of FLT3-ITD or NPM1 mutations among the French population (Rocquain et al., 2010). Although FLT3-ITDmut was rare in MDS, it was associated with a progression to AML (Bains et al., 2011).

The frequency of gene mutations in normal karyotype patients was lower compared to other studies. Moreover, coexisting mutations in this study were AMLFLT3/NPM1, AMLFLT3/DNMT3A, and AMLNPM1/DNMT3A, while AMLFLT3/NPM1/DNMT3A was not detected. Patients with AMLNPM1/DNMT3A had a shorter overall survival (OS) and event free survival (EFS) than AMLFLT3/NPM1 and AMLFLT3/NPM1/DNMT3A presented the worst clinical outcomes (Loghavi et al., 2014). Factors of genetic background, lifestyle and environmental carcinogens might contribute to differences in mutation patterns. Moreover, laboratory methods and sample size of the study may lead to different frequency and mutation type.

In spite of the determination that effective treatment is hopeful for all AML and MDS patients, effective prevention of the disease is also an extremely important factor. The three gene mutations in this population were associated with the age ≤ 60 years and a history of hypertension. In this study, the median age of the mutant patients was lower than the wild type (50.5 vs 56.5 years). The risk of gene mutations increased among patients ≤ 60 years. From another report in Thailand, the age of Thai AML patients was typically younger than Western patients (Auewarakul et al., 2003). According to the importance of age-related susceptibility to environmental toxins, it was reported that the epithelial tissues of adolescence or young adulthood were sensitive life stages for increasing cell proliferation (Perera, 1997). Nagasaki atomic bomb survivors who were exposed at a younger age had a high risk of cancer (Nakashima et al., 2008).

In this research, patients with a history of hypertension had an increased risk of mutation compared to those without. Previous reports on MDS in Thailand showed that 54.7% of MDS had co-morbid diseases involving hypertension (Mancehedtha et al., 2011). The association between hypertension and leukemia is still limited. However, there have been reports concerning hypertension associated with an increased risk of various cancers. Both men and women with hypertension tended to have an increased risk of kidney cancer and other types of cancers (Radisaukas et al., 2016). Likewise, meta-analysis researches indicated that hypertension was associated with an increased risk of prostate cancer (Liang et al., 2016) and endometrial cancer (Aune et al., 2017). The mechanism of hypertension and risk of cancer is still unclear, especially regarding gene mutations. It was observed that persons with high blood pressure had an increased chemical reactivity of lymphocytes to carcinogen exposure leading to an accumulation of DNA damage when compared with persons with normal blood pressure (Pero et al., 1976). Furthermore, individuals who have increased diastolic blood pressure tended to have chromosomal aberrations, particularly chromatid breaks (Pero et al., 1976).

In summary, the frequency of FLT3-ITD, NPM1, and DNMT3A mutations in CN-AML patients in upper
Northern Thailand was found to occur at lower rates than in the Western patients. It was different from some Asian countries and other parts of Thailand. No mutation of these genes was observed in CN-MDS. Some types of these gene mutation differed from previous studies. These may be attributed to the different geography, lifestyle, and genetic background. The age ≤60 years and history of hypertension were found to be significantly associated with an increased the mutations of these three genes. The other factors may not be involved with inducing myeloid leukemogenesis via the pathway of FLT3-ITD, NPM1, and DNMT3A mutations in patients living in upper Northern Thailand. The investigation of these three genes in the intermediate risk group with a normal karyotype is useful for a better understanding of the molecular leukemogenic steps in CN-AML and CN-MDS patients. Furthermore, this study may be beneficial for planning treatment of the patients or cancer prevention in the population of upper Northern Thailand in the future.

Our research findings are worth further study on other gene mutations and the specific details of each risk factor with an increased number of test subjects that will confirm the importance of environmental factors influencing gene mutations.

Conflict of Interest
The authors declare no conflicts of interest.

Acknowledgements
This research was supported by Faculty of Medicine Research Fund, Chiang Mai University, Chiang Mai, Thailand [grant numbers ANA-2558-02820]. Ms. Piyanan Mevatee is a PhD candidate in the Department of Anatomy, Chiang Mai University whose education was supported by the College of Medicine and Public Health, Ubon Ratchathani University, Ubon Ratchathani, Thailand. We would like to thank all members of the Medical Cytogenetics Laboratory at the Department of Anatomy, Medical Science Research Equipment Center, Faculty of Medicine, Chiang Mai University. We are grateful to Mrs. Rochana Phuackchantuck from the Research Administration Section, Faculty of Medicine, Chiang Mai University for her assistance. Importantly, the authors would like to thank all patients who participated in this study and provided us with samples and important information.

References
Ahmad F, Mandava S, Das BR (2010). Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Invest, 28, 63-73.

Ahmad F, Mohota R, Sanap S, et al (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J Cancer Prev, 15, 1247-53.

Auwarakul CU, Promsuwicha O, Y’ UP, et al (2003). Immunophenotypic profile of adult acute myeloid leukemia (AML): analysis of 267 cases in Thailand. Asian Pac J Allergy Immunol, 21, 153-60.

Auwarakul CU, Sritana N, Limwongse C, et al (2005). Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet Cytogenet, 162, 127-34.

Aune D, Sen A, Vatten LI (2017). Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. Sci Rep, 7, 44808.

Bains A, Luthra R, Medeiros LJ, et al (2011). FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol, 135, 62-9.

Boonthimat C, Thongnoppakhun W, Auwarakul CU (2008). Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica, 93, 1565-9.

Borer RA, Lehner CF, Epfenberger HM, et al (1989). Major nuclear proteins shuttle between nucleus and cytoplasm. Cell, 56, 379-90.

Brenner C, Fuku F (2006). DNA methyltransferases: facts, clues, mysteries. Curr Top Microbiol Immunol, 301, 45-66.

Colombo E, Martinelli P, Zamponi R, et al (2006). Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res, 66, 3044-50.

Dohner K, Schlenk RF, Hiddmank D, et al (2005). Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740-6.

El Ghannam D, Taalab MM, Ghazy HF, et al (2014). DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome. Blood Cells Mol Dis, 53, 61-6.

Falini B, Mecucci C, Tiacci E, et al (2005). Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med, 352, 254-66.

Fernandez-Mercado M, Yip BH, Pellagatti A, et al (2012). Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One, 7, e42334.

Gregory TK, Wald D, Chen Y, et al (2009). Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol, 2, 23.

Grimwade D, Walker H, Oliver F, et al (2000). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood, 92, 2322-33.

Grossmann Y, Schnittger S, Kohlmann A, et al (2012). A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood, 120, 2963-72.

Holz-Schietinger C, Matje DM, Reich NO (2012). Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem, 287, 30941-51.

Hou HA, Kuo YY, Liu CY, et al (2012). DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 119, 559-68.

Imsamran W, Chaiwerawattana A, Wiangnon S, et al (2015). Determination of incidence and identification of a novel NPM1 mutation in patients with acute myeloid leukemia. Allergy Immunol (AML): analysis of 267 cases in Thailand. Asian Pac J Allergy Immunol, 21, 153-60.

Auewarakul CU, Sritana N, Limwongse C, et al (2005). Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet Cytogenet, 162, 127-34.
